On 29 MAY Anika Therapeutics, Inc. (NASDAQ:ANIK) reported $0.97 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.25 by $0.72. The company had revenue of $34.00 million for the quarter, compared to the consensus estimate of $16.03 million. During the same quarter in the prior year, the company posted $0.21 earnings per share. The company’s quarterly revenue was up 123.7% on a year-over-year basis. On average, analysts predict that Anika Therapeutics will post $2.22 earnings per share for the current fiscal year. Anika Therapeutics, Inc. (NASDAQ:ANIK) net profit margin is 34.80% and weekly performance is -6.19%. On last trading day company shares ended up $44.87. Analysts mean target price for the company is $57.00. Anika Therapeutics, Inc. (NASDAQ:ANIK) distance from 50-day simple moving average (SMA50) is 1.70%.
Oncomed Pharmaceuticals Inc (NASDAQ:OMED) will present data for a novel assay developed with researchers at MolecularMD, Inc. to identify Notch1 mutation status in patients with certain hematologic malignancies. These data are being presented at the 19th European Hematology Association (EHA) Congress. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) shares fell -8.80% in last trading session and ended the day on $22.71. OMED return on assets is -18.80%. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) quarterly performance is -31.58%.
On 12 JUNE Marcus & Millichap Inc (NYSE:MMI) announced that it sold the Storage Banc portfolio, a seven-property 404,578-net-rentable-square-foot self-storage portfolio in the St. Louis area. Marcus & Millichap Inc (NYSE:MMI) shares moved down -5.50% in last trading session and was closed at $24.05, while trading in range of $23.61 – $25.47 Marcus & Millichap Inc (NYSE:MMI) year to date (YTD) performance is 61.41%.
On 12 JUNE Finisar Corporation (NASDAQ:FNSR) reported Q4 EPS of $0.36, $0.02 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $306.03 million versus the consensus estimate of $303.92 million. Finisar Corporation (NASDAQ:FNSR) ended the last trading day at $19.71. Company weekly volatility is calculated as 2.64% and price to cash ratio as 3.44. Finisar Corporation (NASDAQ:FNSR) showed a negative weekly performance of -20.17%.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.01. On average, analysts predict that Achillion Pharmaceuticals will post $-0.77 earnings per share for the current fiscal year. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) weekly performance is 124.65%. On last trading day company shares ended up $6.47. Analysts mean target price for the company is $5.44. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) distance from 50-day simple moving average (SMA50) is 106.68%.